Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05230901
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
PF-05230901 is a monoclonal antibody that was developed by Pfizer for the treatment of cachexia, particularly chemotherapy-induced and cancer-induced cachexia. The drug was administered subcutaneously and reached phase 1 clinical trials, where its safety, tolerability, and pharmacokinetics were evaluated in healthy volunteers. The precise mechanism of action remains undefined or unknown in public sources. Development of PF-05230901 was discontinued after phase 1 trials[1][2][3][4].
Beyond the preview
Go deeper on PF-05230901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05230901.